Clinical trial
A Phase II Controlled Trial of Velafermin for Prevention of Oral Mucositis
NCT00323518 · CuraGen Corporation, Industry · Completed
Key facts
| NCT number | NCT00323518 |
|---|---|
| Title | A Phase II Controlled Trial of Velafermin for Prevention of Oral Mucositis |
| Official title | A Phase II Randomized Double Blind Placebo Controlled Trial to Assess Safety and Efficacy of Velafermin for Prevention of Oral Mucositis in Hematologic Cancer Patients Receiving Autologous Stem Cell Transplant |
| Lead sponsor | CuraGen Corporation, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Oral Mucositis, Stomatitis |
| Intervention type | Drug |
| Interventions | velafermin, placebo |
| Enrollment | 390 |
| Start date | May 1, 2006 |
| Primary completion | Aug 1, 2008 |
| Completion | Aug 1, 2008 |
| First posted | May 9, 2006 |
| Last update posted | Apr 13, 2016 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: